Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOST Plus: Maintenance Treatment Targeting Tumor Molecular Alterations in Solid Tumors
NCT02029001Phase 2Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Mar 2014
- Primary completion
- Jan 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nilotinib, everolimus, sorafenib, lapatinib, pazopanib and 3 more in solid tumor (2 arms), sponsored by Centre Léon Bérard. Primary endpoints: Induction Progression-Free Rate after induction treatment at 52 weeks and Progression-Free Survival at 16 weeks. Started Mar 2014; status: recruiting.
02
Drugs
nilotinibeverolimussorafeniblapatinibpazopanib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02029001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029001.